Statistics
Status: Monday, 04. September 2023
12976 completed cases
| Male patients | 6057 | 47% |
| Female patients | 6919 | 53% |
| Children and youths | 3077 | 24% |
| Adults | 9899 | 76% |
completed cases per country:
| Germany | 9548 | 74% |
| Austria | 1093 | 8% |
| Switzerland | 2335 | 18% |
1804 completed cases
| Male patients | 981 | 54% |
| Female patients | 823 | 46% |
| Children and youths | 830 | 46% |
| Adults | 974 | 54% |
3046 completed cases
| Male patients | 1688 | 55% |
| Female patients | 1358 | 45% |
| Children and youths | 1249 | 41% |
| Adults | 1797 | 59% |
completed cases per country:
| Brazil | 223 | 7% |
| Bulgaria | 255 | 8% |
| Greece | 422 | 14% |
| Ireland | 215 | 7% |
| Italy | 811 | 27% |
| Poland | 433 | 14% |
| Spain | 605 | 20% |
| Romania | 81 | 3% |
| Netherlands | 1 | 0% |
306 completed cases
| Male patients | 162 | 53% |
| Female patients | 144 | 47% |
| Children and youths | 265 | 87% |
| Adults | 41 | 13% |
Welcome
The Anaphylaxis Registry (NORA - Network for Online-Registration of Anaphylaxis) aims to collect data on severe allergic reactions.
An anaphylactic shock is the most serious, and possibly fatal, result of an allergic reaction. Until now severe allergic reactions are not reported in a standardized manner.
Within this project we aim to obtain information about triggers, cofactors and treatment of patients who experienced a severe allergic reaction. Such data will help to improve the knowledge and treatment modalities of affected patients.